1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6F6AD47BAEDBE690385257CA80070E330
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-cariprazine-the-market-landscape-for-a-second-generation-atypical-antipsychotic?OpenDocument
18
19OpenDocument
203.231.229.89
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing New Product Development and Launch Planning and Coordinating Launch Launch Strategy and Structure

Cariprazine: The Market Landscape for a Second-Generation Atypical Antipsychotic

DB Image

ID: 5302


Features:

1 Info Graphics


Pages/Slides: 4


Published: 2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
STUDY OVERVIEW


This short case study examines cariprazine, a second-generation atypical antipsychotic therapy developed by Forest Laboratories and Gedeon Richter. Given the nature of the CNS market, where individual patients do not experience the same outcomes or the same side effects with the same therapy, each new antipsychotic medicine gives physicians one more option to try.

That creates an opportunity for acceptance of new products, even in a crowded market.

This study reviews cariprazine and the drug's potential, its pros and cons and where the product could fit into the antipsychotic market.


Industries Profiled:
Pharmaceutical


Companies Profiled:
Forest Laboratories; Gedeon Richter Ltd.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.